To investigate how nivolumab influenced PB lymphocyte sub-populations and tumor burden, we determined the counts/ml of CD45+ leukocytes, CD4+ SS cells, and total CD4+ and CD8+ T cells at T0 and after selected nivolumab administrations up to 42 weeks (T42) from the start of therapy. Here, PTPRC is linked to neoplasm.